The decision comes amid declining demand for the company’s HPV vaccine Gardasil and only a year after the $1 billion site was announced.

The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities.  | In a Worker Adjustment and Retraining Notification Act alert filed this ...

Feb 27 (Reuters) - Merck will lay off about 150 employees across its facility in North Carolina that manufactures its human papillomavirus vaccine, Gardasil, according to a notice filed in the state's ...

Merck says Keytruda boosted overall survival in phase 3 ovarian cancer trial and cut death risk in bladder cancer combo data.

The drugmaker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...

By Padmanabhan Ananthan Feb 23 (Reuters) - Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for ...

Merck is preparing to cut about 150 jobs at its new vaccine plant in Durham, North Carolina, a move that ties a very local ...

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...

Merck & Co. is cutting staff at a US plant that makes its HPV vaccine Gardasil amid a decrease in global demand for the cancer-preventing shot.

Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Keytruda for certain patients with ...